Author: Hormone Insight Editorial Team

Summary: In 1,145 patients with obesity-related HFpEF (LVEF ≥45%, BMI ≥30 kg/m²) from the pooled STEP-HFpEF trials, semaglutide 2.4 mg subcutaneous injection weekly significantly reduced NT-proBNP by 18% (treatment ratio 0.82, P=0.0002) and improved health status, with greater KCCQ benefits (up to 11.9 points) in higher baseline NT-proBNP tertiles compared to matching placebo, with consistent weight loss across NT-proBNP tertiles and no significant safety concerns. PICO Description Population 1,145 patients with obesity-related HFpEF (LVEF ≥45%, BMI ≥30) from STEP-HFpEF trials. Intervention Semaglutide 2.4 mg subcutaneous weekly, titrated over 16 weeks. Comparison Matching placebo injection weekly. Outcome NT-proBNP reduced 18%. KCCQ…

Read More